Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Showkat Hamid
Institutions:
Roswell Park Comprehensive Cancer Center,
Moffitt Cancer Center
Observed institutions:
Roswell Park Comprehensive Cancer Center,
Moffitt Cancer Center
ORCID:
0009-0005-6016-9515
Observed ORCID:
0009-0005-6016-9515
OpenAlex ID:
A5101290232
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
2025
·
Timothy J. Voorhees
, Eric M. McLaughlin
, et al.
·
Blood Cancer Journal
·
19
Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center
2023
·
Michelle Walter
, Eric Hansen
, et al.
·
Journal of Pain and Symptom Management
·
15
PDF
IFN-γ–driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy
2025
·
Payal Goala
, Yongliang Zhang
, et al.
·
Journal of Clinical Investigation
·
11
IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
2026
·
Sae Bom Lee
, Allan Pavy
, et al.
·
Nature Communications
·
6
PDF
Effect of prophylactic corticosteroids on toxicities and outcomes in CAR T-cell therapy: A cohort study.
2025
·
Anuja Vidyadhar Abhyankar
, Megan Herr
, et al.
·
Journal of Clinical Oncology
·
2
CAR T cell-driven induction of iNOS in tumor associated macrophages promotes CAR T cell resistance in B cell lymphoma
2025
·
Sae Bom Lee
, Yun Pyo Kang
, et al.
·
Blood
·
1
PDF
Abstract 4800: Modulation of Th1/Th17 axis through IFNγ-blockade alleviates Anti-CD19 CAR-T associated toxicities in a pre-clinical immune competent model
2025
·
Payal Goala
, Marco Davila
, et al.
·
Cancer Research
·
1
Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers
2023
·
Timothy Voorhees
, Eric McLaughlin
, et al.
·
Blood
·
1
PDF
Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy
2026
·
Michael D Jain
, Alaa Ali
, et al.
·
Blood Advances
PDF
Motixafortide Is Effective in Hematopoietic Progenitor Cell Mobilization in Multiple Myeloma Patients Treated with Quadruplet Therapy
2026
·
Hanna Bailey
, Elizabeth DiMaggio
, et al.
·
Transplantation and Cellular Therapy
Adverse Drug Effects Following Motixafortide for Hematopoietic Progenitor Cell Mobilization in Patients with Multiple Myeloma
2026
·
Elizabeth DiMaggio
, Hanna Bailey
, et al.
·
Transplantation and Cellular Therapy
In-depth, quantitative characterization of important regulators and predictive biomarkers for CAR T-cell therapy induced toxicities in a clinical cohort
2025
·
Min Ma
, Muhammad Junaid Tariq
, et al.
·
Blood
PDF
POSTER: AML-983 Evaluating ChatGPT’s Responses to Commonly AskedQuestions in Allogeneic Hematopoietic Stem Cell Transplantation: A Physician-Based Assessment
2025
·
Safa Saadat Afridi
, Sumbal Aziz
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
AML-983: Evaluating ChatGPT's Responses to Commonly Asked Questions in Allogeneic Hematopoietic Stem Cell Transplantation: A Physician-Based Assessment
2025
·
Safa Saadat Afridi
, Sumbal Aziz
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Dasatinib for Steroid Refractory Icans – a Single Center Experience
2025
·
Muhammad Junaid Tariq
, Showkat Hamid
, et al.
·
Transplantation and Cellular Therapy
Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
2024
·
Muhammad Junaid Tariq
, Kristopher Attwood
, et al.
·
Blood
PDF
Correlation of Serum Inflammatory State and Macrophage Phenotype with CAR T Cell Expansion and Clinical Outcomes
2024
·
Showkat Hamid
, Muhammad Junaid Tariq
, et al.
·
Blood
Disease Control Affects Outcomes of Patients with Relapsed Diffuse Large B Cell Lymphoma Treated with CD19 Directed CAR T-Cell Therapy
2023
·
Dorothy C Pan
, Showkat Hamid
, et al.
·
Blood
PDF
Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers
2023
·
Timothy Voorhees
, Natalie S. Grover
, et al.
·
Blood
Treatment Selection and Clinical Outcomes in Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia (LPL/WM) - a Single Center Analysis
2023
·
Muhammad Junaid Tariq
, Andrea Carolina Anampa-Guzmán
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
20
Citation count:
56
H-index:
4
I10-index:
3
Year
Topic
Type